# CERTIFICATION

I, Paul Averback, certify
that:

|1. | I
have reviewed this annual report on Form 20-F of Nymox Pharmaceutical
                    Corporation;
|-- | --------------------------------------------------------------------------------------------------------

|2. | Based
on my knowledge, this report does not contain any untrue statement of a
                    material fact or omit to state a material fact necessary to make the
statements                     made, in light of the circumstances under which such
statements were made, not                     misleading with respect to the period
covered by this report;
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|3. | Based
on my knowledge, the financial statements, and other financial information
                    included in this report, fairly present in all material respects the
financial                     condition, results of operations and cash flows of the
company as of, and for,                     the periods presented in this report;
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|4. | The
companys other certifying officer and I are responsible for
                    establishing and maintaining disclosure controls and procedures (as
defined in                     Exchange Act Rules 13a  15(e) and 15d  15(e)),
and internal control                     over financial reporting (as defined in the
Exchange Act Rules 13a15(f)                     and 15d15(f)) for the company
and we have:
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | a)
designed such disclosure controls and procedures, or caused such disclosure
          controls and  procedures to be designed under our supervision, to ensure
          that material information relating to the company, including its consolidated
          subsidiaries, is made known to us by others within those entities, particularly
          during the period in which this report is being prepared;
| | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | b)
designed such internal control over financial reporting, or caused such
          internal control over financial reporting to be designed under our supervision,
          to provide reasonable assurance regarding the reliability of financial
reporting           and the preparation of financial statements for external purposes in
accordance           with generally accepted accounting principles;
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | c)
evaluated the effectiveness of the companys disclosure controls and
          procedures and presented in this report our conclusions about the effectiveness
          of the disclosures and procedures, as of the end of the period covered by this
          report based on such evaluation; and
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | d)
            disclosed in this report any change in the companys internal control
over           financial reporting that occurred during the period covered by the annual
report           that has materially affected, or is reasonably likely to materially
affect, the           companys internal control over financial reporting; and
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|5. | The
companys other certifying officer(s) and I have disclosed, based on
                    our most recent evaluation of internal control over financial
reporting, to the                     companys auditors and the audit committee of
companys board of                     directors (or persons performing the
equivalent function):
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | a)
            All significant deficiencies and material weaknesses in the design or
operation           of internal control over financial reporting which are reasonably
likely to           adversely affect the companys ability to record, process,
summarize and           report financial information; and
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | b)
            Any fraud, whether or not material, that involves management or other
employees           who have a significant role in the companys internal control
over           financial reporting.
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: April 28, 2008

| | /s/
Paul Averback, MD  Paul Averback, MDPresident and Chief Executive OfficerNymox
Pharmaceutical Corporation
| | -------------------------------------------------------------------------------------------------------------